This important trial will be conducted in 4 countries across Europe and aims to demonstrate the power of immune tolerizing approaches for patients with multiple sclerosis.

Cellerys AG, the startup of the ETIMSred project enters into a collaboration with Novartis.

Stem cell transplantation in Multiple Sclerosis is a promising therapy but has not been approved in Switzerland so far. Now, the Swiss Federal Office of Public Health announced, that as of July 1, 2018, health insurers will have to cover the costs of this therapy.